ONKT104 / ONK Therap, Cellerant Therap - LARVOL DELTA

European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies (GlobeNewswire) - "ONK Therapeutics Ltd...today announced that the European Patent Office (EPO) has granted its licensed patent covering CISH knockout (KO) in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells (iPSCs)....The patent granted by EPO specifically covers CISH KO NK cells per se, and cancer therapies that utilize NK cells with CISH KO as well as NK cells engineered with the foundational CISH KO in combination with IL-15 (soluble or engineered), TGFβR2 KO, or TGFβR2 KO and IL-15 (soluble or engineered)."

Patent • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies (Businesswire) - "ONK Therapeutics...announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management....The financing will enable ONK to maintain its strong momentum as it advances pre-clinical programs through comprehensive IND-enabling studies, including in-vivo proof-of-concept models across multiple programs."

Financing • Acute Myelogenous Leukemia • Breast Cancer • Gynecologic Cancers • Hematological Malignancies • Leukemia • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline (Businesswire) - "Three new exclusive option license agreements expand the depth and breadth of ONK’s pre-clinical pipeline; A humanized scFv targeting CLEC12A licensed from Cellerant Therapeutics, creates a fourth pre-clinical program, ONKT104, for the treatment of acute myeloid leukemia (AML); A humanized scFv targeting a novel tumor-specific MUC1 glycopeptide epitopelicensed from Glycotope GmbH, strengthens pre-clinical program ONKT103, for solid tumors; A CCR7 homing receptor licensed from the National Institute of Health (NIH), for use in the pre-clinical ONKT101 program, for relapsed/refractory B cell malignancies."

Licensing / partnership • Acute Myelogenous Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Oncology • Solid Tumor